Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
Go back to Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025| AdvanSource Biomaterials Corpration (AMEX: ASNB) | Delayed: 0.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.85 | 52 Week High | $0.41 | |||
| Open | $7.87 | 52 Week Low | $0.05 | |||
| Day High | $0.85 | P/E | N/A | |||
| Day Low | $0.85 | EPS | $-0.12 | |||
| Volume | 80 | |||||
| NORD ANGLIA EDUCATION, Inc. (AMEX: NORD) | Delayed: 1.90 -0.05 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.95 | 52 Week High | $23.88 | |||
| Open | $2.10 | 52 Week Low | $14.58 | |||
| Day High | $2.10 | P/E | N/A | |||
| Day Low | $1.90 | EPS | $0.00 | |||
| Volume | 1,502 | |||||
